Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$798M |
| 2 |
Netflix
NFLX
|
+$608M |
| 3 |
UnitedHealth
UNH
|
+$517M |
| 4 |
Apple
AAPL
|
+$461M |
| 5 |
GE Vernova
GEV
|
+$296M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Broadcom
AVGO
|
+$527M |
| 2 |
Alphabet (Google) Class A
GOOGL
|
+$372M |
| 3 |
Meta Platforms (Facebook)
META
|
+$362M |
| 4 |
Advanced Micro Devices
AMD
|
+$328M |
| 5 |
Palantir
PLTR
|
+$327M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.57% |
| 2 | Healthcare | 15.8% |
| 3 | Consumer Discretionary | 12.38% |
| 4 | Financials | 11.53% |
| 5 | Industrials | 8.92% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2126
Keros Therapeutics
KROS
$222M
| $1.96M | ﹤0.01% |
+146,600
| New | +$1.98M |
|
2127
Agilon Health
AGL
$1.45B
| $1.96M | ﹤0.01% |
34,000
-17,640
| -34% | -$1.41M |
|
2128
Editas Medicine
EDIT
$432M
| $1.95M | ﹤0.01% |
888,400
-144,565
| -14% | -$237K |
|
2129
Semtech
SMTC
$12.4B
| $1.95M | ﹤0.01% |
43,216
+30,200
| +232% | +$1.07M |
|
2130
Assembly Biosciences
ASMB
$536M
| $1.95M | ﹤0.01% |
107,521
-5,790
| -5% | -$76.4K |
|
|
EFXT
2131
Enerflex
EFXT
$2.62B
| $1.94M | ﹤0.01% |
246,300
+32,700
| +15% | +$234K |
|
2132
HUTCHMED
HCM
$2.13B
| $1.94M | ﹤0.01% |
129,000
-6,200
| -5% | -$90.6K |
|
2133
AXIS Capital
AXS
$7.26B
| $1.94M | ﹤0.01% |
18,700
-20,000
| -52% | -$1.99M |
|
2134
iShares Core MSCI Total International Stock ETF
IXUS
$60.8B
| $1.94M | ﹤0.01% |
25,100
+300
| +1% | +$21.9K |
|
2135
Lightpath Technologies
LPTH
$824M
| $1.94M | ﹤0.01% |
629,347
-20,998
| -3% | -$52.1K |
|
|
IAS
2136
DELISTED
Integral Ad Science
IAS
| $1.93M | ﹤0.01% |
232,300
-207,700
| -47% | -$1.58M |
|
2137
Zumiez
ZUMZ
$318M
| $1.92M | ﹤0.01% |
144,900
+14,900
| +11% | +$188K |
|
2138
Maui Land & Pineapple Co
MLP
$310M
| $1.92M | ﹤0.01% |
105,549
+900
| +0.9% | +$14.6K |
|
2139
Eagle Bancorp
EGBN
$877M
| $1.9M | ﹤0.01% |
97,680
+39,980
| +69% | +$742K |
|
2140
Liberty Live Group Series A
LLYVA
$9.59B
| $1.9M | ﹤0.01% |
23,900
-39,200
| -62% | -$2.85M |
|
2141
Five Star Bancorp
FSBC
$1.16B
| $1.9M | ﹤0.01% |
66,500
-8,700
| -12% | -$239K |
|
2142
Village Farms International
VFF
$302M
| $1.89M | ﹤0.01% |
1,722,066
+759,013
| +79% | +$672K |
|
2143
Chesapeake Utilities
CPK
$3.25B
| $1.89M | ﹤0.01% |
+15,750
| New | +$1.98M |
|
2144
Laird Superfood
LSF
$48.2M
| $1.89M | ﹤0.01% |
300,500
+25,200
| +9% | +$157K |
|
2145
Granite Construction
GVA
$5.41B
| $1.89M | ﹤0.01% |
20,200
-3,700
| -15% | -$312K |
|
2146
Allogene Therapeutics
ALLO
$683M
| $1.89M | ﹤0.01% |
1,670,012
+113,312
| +7% | +$151K |
|
|
INZY
2147
DELISTED
Inozyme Pharma
INZY
| $1.88M | ﹤0.01% |
470,500
-93,954
| -17% | -$233K |
|
2148
Sight Sciences
SGHT
$456M
| $1.88M | ﹤0.01% |
455,026
-152,251
| -25% | -$508K |
|
2149
CorMedix
CRMD
$639M
| $1.88M | ﹤0.01% |
+152,200
| New | +$1.68M |
|
2150
Flexible Solutions
FSI
$63.1M
| $1.87M | ﹤0.01% |
386,442
-4,203
| -1% | -$17.6K |
|
Similar funds
Jim Simons's Q2 2025 Portfolio in Review
As of Q2 2025, Jim Simons held 4,018 positions worth $75.2B, up 14% from $66.1B the previous quarter. Its ten largest holdings account for 12% of the portfolio.
Jim Simons's Q2 2025 filing shows 612 new, 1,577 increased, 1,314 reduced and 496 closed positions. Its largest new stake was UnitedHealth: 1,352,129 shares worth $422M. The largest sale was Broadcom, an estimated $527M.
By sector, the portfolio is most concentrated in Technology at 20% of assets, up from 17% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- Jim Simons's largest Q2 2025 buy was UnitedHealth: 1,352,129 shares worth $422M.
- Jim Simons added most to NVIDIA in Q2 2025, an estimated $798M increase.
- Jim Simons's biggest Q2 2025 reduction was Broadcom, cutting an estimated $527M.
- Jim Simons fully exited Advanced Micro Devices in Q2 2025, selling an estimated $328M.
- Jim Simons's ten largest holdings make up 12% of its $75.2B portfolio in Q2 2025.
- Jim Simons opened 612 new positions and closed 496 in Q2 2025.
- Jim Simons's portfolio value rose 14% quarter-over-quarter to $75.2B.
Based on Renaissance Technologies's 13F filing for Q2 2025, filed 13 Aug 2025.